Article (Scientific journals)
Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.
Piron, Maude; Loo, Martine; Gothot, André et al.
2001In Blood, 97 (2), p. 442-8
Peer Reviewed verified by ORBi
 

Files


Full Text
Epo-rat-stop-Blood 2001.pdf
Publisher postprint (133.07 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anemia/chemically induced; Animals; Bone Marrow Cells/drug effects/metabolism; Erythroid Precursor Cells/drug effects; Erythropoiesis/drug effects; Erythropoietin, Recombinant/administration & dosage/adverse effects/blood; Hematocrit; Humans; Iron Overload/chemically induced/drug therapy; Iron, Dietary/administration & dosage; Male; Rats; Rats, Wistar; Receptors, Transferrin/drug effects; Reticulocyte Count; Spleen/cytology/drug effects; Splenectomy; Substance Withdrawal Syndrome/blood/physiopathology; Time Factors
Abstract :
[en] Little information is available on the evolution of erythropoiesis after interruption of recombinant human erythropoietin (rHuEpo) therapy. Iron-overloaded rats received 20 daily injections of rHuEpo. During treatment, reticulocytes, soluble transferrin receptor (sTfR), and hematocrit increased progressively. This was accompanied by a substantial expansion of spleen erythropoiesis but a decrease in the bone marrow. Five weeks after treatment, rats developed a significant degree of a regenerative anemia. Erythropoietic activity, as assessed by reticulocytes, sTfR, erythroid cellularity, iron incorporation into heme, and the number of erythroid colonies, was severely depressed 3 weeks after cessation of rHuEpo. This was followed by regeneration of erythroblasts and reticulocytes at weeks 6 to 7 post-Epo, but erythroid progenitors recovered only partially by that time. The anemia was definitely corrected 2 months after cessation of rHuEpo treatment. Serum Epo levels remained elevated for several weeks, but the sensitivity of marrow erythroid precursors to Epo was preserved. No rat antibodies to rHuEpo were detected, and serum from post-Epo animals did not exert any inhibitory activity on erythropoiesis. In conclusion, after cessation of intensive rHuEpo therapy, there was a strong inhibition of erythropoietic activity with secondary anemia followed by late recovery. This was not due to antibodies or other soluble inhibitory factors, a defect in endogenous Epo production, or a loss of sensitivity to Epo. This may rather represent intrinsic erythroid marrow exhaustion, mostly at the level of erythroid progenitors but also at later stages of erythropoiesis.
Disciplines :
Hematology
Author, co-author :
Piron, Maude ;  Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Loo, Martine
Gothot, André ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Tassin, Françoise ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Fillet, Georges ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Beguin, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.
Publication date :
2001
Journal title :
Blood
ISSN :
0006-4971
eISSN :
1528-0020
Publisher :
American Society of Hematology, Washington, United States - District of Columbia
Volume :
97
Issue :
2
Pages :
442-8
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 25 February 2009

Statistics


Number of views
87 (8 by ULiège)
Number of downloads
831 (4 by ULiège)

Scopus citations®
 
29
Scopus citations®
without self-citations
26
OpenCitations
 
20

Bibliography


Similar publications



Contact ORBi